
|Articles|August 1, 2004
Older drugs' photoreactivity cataloged
Chicago - Tracking the photoreactivity of many medicines that predate U.S. Food and Drug Administration requirements in this area has been an inexact science, but it's becoming less so. That's because an extensive review released in a presentation at "Important Advances in Allergy-Immunology and Dermatology - From the Bench to the Bedside," a recent gathering of allergists, immunologists and dermatologists in Chicago hosted by Northwestern University, outlines photoreactivity data for more than 100 widely used drugs gleaned from more than 150 research articles
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
3
Introducing Dermatology Times NP/PA Connect
4
Narrow-Spectrum Sarecycline Approved for Moderate to Severe Acne in China
5











